{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T22:37:44Z","timestamp":1722811064651},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00393-020-00789-0","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T14:03:01Z","timestamp":1587564181000},"page":"429-436","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Autologe h\u00e4matopoetische Stammzelltransplantation bei systemischer Sklerose"],"prefix":"10.1007","volume":"79","author":[{"given":"T.","family":"Alexander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H. W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hiepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"issue":"10","key":"789_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/1744666X.2019.1656526","volume":"15","author":"JA Snowden","year":"2019","unstructured":"Snowden\u00a0JA, Badoglio\u00a0M, Alexander\u00a0T (2019) The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party. Expert Rev Clin Immunol 15(10):981\u2013985","journal-title":"Expert Rev Clin Immunol"},{"issue":"9790","key":"789_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt\u00a0RK, Shah\u00a0SJ, Dill\u00a0K, Grant\u00a0T, Gheorghiade\u00a0M, Schroeder\u00a0J et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378(9790):498\u2013506","journal-title":"Lancet"},{"issue":"24","key":"789_CR3","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar\u00a0JM, Farge\u00a0D, Sont\u00a0JK, Naraghi\u00a0K, Marjanovic\u00a0Z, Larghero\u00a0J et\u00a0al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a\u00a0randomized clinical trial. JAMA 311(24):2490\u20132498","journal-title":"JAMA"},{"issue":"1","key":"789_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan\u00a0KM, Goldmuntz\u00a0EA, Keyes-Elstein\u00a0L, McSweeney\u00a0PA, Pinckney\u00a0A, Welch\u00a0B et al (2018) Myeloablative autologous stem-cell transplantation for severe Scleroderma. N\u00a0Engl J Med 378(1):35\u201347","journal-title":"N Engl J Med"},{"key":"789_CR5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230128","author":"J Henes","year":"2020","unstructured":"Henes\u00a0J, Oliveira\u00a0MC, Labopin\u00a0M, Badoglio\u00a0M, Scherer\u00a0HU, Del Papa\u00a0N et al (2020) Autologous stem cell transplantation for progressive systemic sclerosis: a\u00a0prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.230128","journal-title":"Haematologica"},{"issue":"27","key":"789_CR6","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","volume":"1","author":"JA Snowden","year":"2017","unstructured":"Snowden\u00a0JA, Badoglio\u00a0M, Labopin\u00a0M, Giebel\u00a0S, McGrath\u00a0E, Marjanovic\u00a0Z et\u00a0al (2017) Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv 1(27):2742\u20132755","journal-title":"Blood Adv"},{"issue":"10","key":"789_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/sj.bmt.1704656","volume":"34","author":"R Saccardi","year":"2004","unstructured":"Saccardi\u00a0R, Tyndall\u00a0A, Coghlan\u00a0G, Denton\u00a0C, Edan\u00a0G, Emdin\u00a0M et\u00a0al (2004) Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant 34(10):877\u2013881","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"789_CR8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1182\/blood-2011-02-336156","volume":"118","author":"T Daikeler","year":"2011","unstructured":"Daikeler\u00a0T, Labopin\u00a0M, Di Gioia\u00a0M, Abinun\u00a0M, Alexander\u00a0T, Miniati\u00a0I et\u00a0al (2011) Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a\u00a0retrospective study of the EBMT Autoimmune Disease Working Party. Blood 118(6):1693\u20131698","journal-title":"Blood"},{"issue":"6","key":"789_CR9","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/blood-2006-07-035766","volume":"109","author":"Y Loh","year":"2007","unstructured":"Loh\u00a0Y, Oyama\u00a0Y, Statkute\u00a0L, Quigley\u00a0K, Yaung\u00a0K, Gonda\u00a0E et\u00a0al (2007) Development of a\u00a0secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 109(6):2643\u20132548","journal-title":"Blood"},{"issue":"5","key":"789_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/bmt.2014.325","volume":"50","author":"I Vaxman","year":"2015","unstructured":"Vaxman\u00a0I, Ram\u00a0R, Gafter-Gvili\u00a0A, Vidal\u00a0L, Yeshurun\u00a0M, Lahav\u00a0M et al (2015) Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis. Bone Marrow Transplant 50(5):706\u2013714","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"789_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1200\/JCO.1988.6.5.813","volume":"6","author":"JE Sanders","year":"1988","unstructured":"Sanders\u00a0JE, Buckner\u00a0CD, Amos\u00a0D, Levy\u00a0W, Appelbaum\u00a0FR, Doney\u00a0K et\u00a0al (1988) Ovarian function following marrow transplantation for aplastic anemia or leukemia. J\u00a0Clin Oncol 6(5):813\u2013818","journal-title":"J Clin Oncol"},{"issue":"2","key":"789_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2014.248","volume":"50","author":"E Snarski","year":"2015","unstructured":"Snarski\u00a0E, Snowden\u00a0JA, Oliveira\u00a0MC, Simoes\u00a0B, Badoglio\u00a0M, Carlson\u00a0K et\u00a0al (2015) Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a\u00a0retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplant 50(2):216\u2013220","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"789_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/bmt.2017.21","volume":"52","author":"JH Dalle","year":"2017","unstructured":"Dalle\u00a0JH, Lucchini\u00a0G, Balduzzi\u00a0A, Ifversen\u00a0M, Jahnukainen\u00a0K, Macklon\u00a0KT et al (2017) State-of-the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a\u00a0report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29\u201330 September 2015. Bone Marrow Transplant 52(7):1029\u20131035","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"789_CR14","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai\u00a0M, Meune\u00a0C, Boubaya\u00a0M, Avouac\u00a0J, Hachulla\u00a0E, Balbir-Gurman\u00a0A et al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76(11):1897\u20131905","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"789_CR15","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","volume":"78","author":"M Becker","year":"2019","unstructured":"Becker\u00a0M, Graf\u00a0N, Sauter\u00a0R, Allanore\u00a0Y, Curram\u00a0J, Denton\u00a0CP et\u00a0al (2019) Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a\u00a0European Scleroderma Trials and Research (EUSTAR) analysis. Ann Rheum Dis 78(9):1242\u20131248","journal-title":"Ann Rheum Dis"},{"key":"789_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez558","author":"C Mihai","year":"2019","unstructured":"Mihai\u00a0C, Distler\u00a0O, Gheorghiu\u00a0AM, Constantin\u00a0PI, Dobrota\u00a0R, Jordan\u00a0S et\u00a0al (2019) Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kez558","journal-title":"Rheumatology"},{"issue":"8","key":"789_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka\u00a0O, Fransen\u00a0J, Avouac\u00a0J, Becker\u00a0M, Kulak\u00a0A, Allanore\u00a0Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"789_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ, Furst\u00a0DE, Khanna\u00a0D, Kleerup\u00a0EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a\u00a0randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"4","key":"789_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrrheum.2018.34","volume":"14","author":"RK Burt","year":"2018","unstructured":"Burt\u00a0RK, Farge\u00a0D (2018) Systemic sclerosis: autologous HSCT is efficacious, but can we make it safer? Nat Rev Rheumatol 14(4):189\u2013191","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"789_CR20","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2017.56","volume":"52","author":"D Farge","year":"2017","unstructured":"Farge\u00a0D, Burt\u00a0RK, Oliveira\u00a0MC, Mousseaux\u00a0E, Rovira\u00a0M, Marjanovic\u00a0Z et\u00a0al (2017) Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant 52(11):1495\u20131503","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"789_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/ejh.12686","volume":"97","author":"N Blank","year":"2016","unstructured":"Blank\u00a0N, Lisenko\u00a0K, Pavel\u00a0P, Bruckner\u00a0T, Ho\u00a0AD, Wuchter\u00a0P (2016) Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease. Eur J Haematol 97(1):78\u201382","journal-title":"Eur J Haematol"},{"issue":"7","key":"789_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/sj.bmt.1700727","volume":"19","author":"A Tyndall","year":"1997","unstructured":"Tyndall\u00a0A, Gratwohl\u00a0A (1997) Blood and marrow stem cell transplants in auto-immune disease: a\u00a0consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 19(7):643\u2013645","journal-title":"Bone Marrow Transplant"},{"issue":"37","key":"789_CR23","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1055\/s-0033-1349503","volume":"138","author":"N Blank","year":"2013","unstructured":"Blank\u00a0N, Lorenz\u00a0HM (2013) Treatment and course of a\u00a0man with systemic sclerosis before and after hematopoetic blood stem cell transplantation. Dtsch Med Wochenschr 138(37):1824\u20131827","journal-title":"Dtsch Med Wochenschr"},{"issue":"5","key":"789_CR24","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/rheumatology\/ket464","volume":"53","author":"JC Henes","year":"2014","unstructured":"Henes\u00a0JC, Koetter\u00a0I, Horger\u00a0M, Schmalzing\u00a0M, Mueller\u00a0K, Eick\u00a0C et al (2014) Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology 53(5):919\u2013922","journal-title":"Rheumatology"},{"issue":"26","key":"789_CR25","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0KB, Gahlemann\u00a0M, Azuma\u00a0A, Fischer\u00a0A, Mayes\u00a0MD et al (2019) Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N\u00a0Engl J Med 380(26):2518\u20132528","journal-title":"N Engl J Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00789-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00789-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00789-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:32:22Z","timestamp":1619047942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00789-0"}},"subtitle":["Positionspapier des Arbeitskreises Stammzelltherapie der Deutschen Gesellschaft f\u00fcr Rheumatologie"],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00789-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"22 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Alexander, J.\u00a0Henes, J.\u00a0Distler, M.\u00a0Schmalzing, N.\u00a0Blank, I.\u00a0K\u00f6tter und F.\u00a0Hiepe geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}